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ABSTRACT
Vitamins are necessary factors in human development 
and normal brain function. Vitamin C is a hydrosoluble 
compound that humans cannot produce; therefore, we are 
completely dependent on food intake for vitamin C. Ascorbic 
acid is an important antioxidative agent and is present in 
high concentrations in neurons and is also crucial for colla-
gen synthesis throughout the body. Ascorbic acid has a role in 
modulating many essential neurotransmitters, enables neu-
rogenesis in adult brain and protects cells against infection. 
While SVCT1 enables the absorption of vitamin C in the in-
testine, SVCT2 is primarily located in the brain.
Ascorbate defi ciency is classically expressed as scurvy, 
which is lethal if not treated. However, subclinical defi cien-
cies are probably much more frequent. Potential fi elds of 
vitamin C therapy are in neurodegenerative, cerebrovascu-
lar and aff ective diseases, cancer, brain trauma and oth-
ers. For example, there is some data on its positive eff ects 
in Alzheimer’s disease. Various dosing regimes are used, but 
ascorbate is safe, even in high doses for protracted periods. 
Better designed studies are needed to elucidate all of the po-
tential therapeutic roles of vitamin C. 
Key words: vitamin C, neurotransmitters, antioxidant, 
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SAŽETAK
Vitamin su neophodni faktori za razvoj i normalnu funk-
ciju mozga kod ljudi. Vitamin C je hidrosolubilno jedinjenje 
koje ljudski organizam ne može da sintetiše tako da smo pot-
puno zavisni od unosa putem hrane. Askorbinska kiselina je 
važno antioksidativno sredstvo i prisutna je u neuronima u 
visokim koncentracijama. Takođe je od ključnog značaja za 
sintezu kolagena u celom organizmu. Askorbinska kiselina 
ima ulogu u modulaciji mnogih bitnih neurotransmitera, 
omogućava neurogenezu u mozgu odraslog i štiti ćelije od 
infekcije. Dok SVCT1 omogućava apsorpciju vitamina C u 
crevima, SVCT2 se nalazi uglavnom u mozgu.
Nedostatak askorbata klasično se ispoljava kao skorbut 
koji je letalan ako se ne leči, ali je supklinička defi cijencija 
verovatno mnogo češća. Potencijalni terapijski domeni vita-
mina C terapije su neurodegenerativne, cerebrovaskularne i 
afektivne bolesti, karcinomi, traume mozga i drugi. Postoje 
na primer podaci o pozitivnim efekatima askorbinske kiseli-
ne u Alchajmerovoj bolesti. Koriste se razni režimi doziranja, 
ali je askorbat pokazao bezbednost čak i u visokim dozama 
tokom dugih perioda. Potrebne su bolje dizajnirane studije 
da se razjasne sve potencijalne terapijske uloge vitamina C.
Ključne reči: vitamin C, neurotransmiteri, antioksidan-
si, kolagen
INTRODUCTION
Some of the functions of vitamins in neurological and 
psychiatric diseases are well known (1). The growing body 
of evidence shows novel roles of vitamins, such as vitamins 
B, D and A, in the brain, with important neuropsychiatric 
implications (2). Vitamin C (ascorbic acid, ascorbate) is a hy-
drosoluble vitamin that is not produced in humans. Vitamin 
C was isolated in the early 1930s. Albert Szent-Györgyi won 
the Nobel Prize in 1937 for his discovery of vitamin C, and 
Linus Pauling, a double Nobel laureate, popularized its use 
for disease prevention and longevity (3).
Vitamin C has important functions in the synthesis of 
collagen (the main component of connective tissues) nor-
adrenalin and carnitine, and in fat, peptide hormone and 
tyrosine metabolism. It is also involved in angiogenesis and 
cell survival (4, 5). Ascorbic acid has a prominent role in 
maintaining healthy bones, teeth, gums and muscles, as 
well as in wound healing, iron absorption and combating 
infections. Another significant role of ascorbic acid is its 
antioxidative protection of proteins, lipids, carbohydrates 
and nucleic acids. 
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death (4). Pseudoparalysis of the limbs occurs because of the 
extreme pain upon movement caused by haemorrhages un-
der the periosteum. The early signs of vitamin C deficiency 
are impaired wound healing due to collagen-related pathol-
ogy, follicular hyperkeratosis, petechial haemorrhages and 
low plasma and leukocyte concentrations. The lowest physi-
ological requirement is approximately 10 mg/day. Symp-
toms occur when ingestion falls lower than 10 mg/day or 
when the whole-body content falls under 300 mg (4).
Between 1988 and 1994 in the United States of Amer-
ica, approximately 15% of adults were vitamin C-deficient 
with plasma levels less than 11 mmol/L, which was likely 
predominantly caused by being overweight (14). 
The main foods with higher levels of ascorbic acid are 
fruit and vegetables, but many people take vitamin C sup-
plements. To correct all signs and symptoms of ascorbic 
acid deficiency, it is necessary for the whole-body vitamin 
C level to reach 1000 mg (7).  
VITAMIN C AND THE BRAIN
Vitamin C is crucial for brain function. Some evidence 
shows that vitamin C is active during brain development in 
stem cell division, neuronal and glial differentiation, matu-
ration, and neurotransmission (15, 5). On the other hand, 
vitamin C deficiency impairs folic acid metabolism and 
presents the clinical manifestation of folic hypovitaminosis 
during pregnancy (15). Brain ascorbate concentrations are 
higher in the CSF than in plasma. 
Ascorbic acid from the blood accumulates in the brain 
and is maintained at high concentrations in neuronal and 
glial cells (16). The ascorbate content in glial cells is substan-
tially lower than in neurons. Ascorbate has different actions 
from other antioxidants, such as vitamin E and glutathione 
(GSH). The newly discovered functions for ascorbate are its 
role as a co-factor in several important enzyme reactions. 
Vitamin C reduces oxidative neuronal stress by protecting 
cell membranes and DNA, reducing beta-amyloid toxicity 
and regenerating other antioxidants, such as vitamin E (17).
The regional distribution of ascorbate in the brain is 
asymmetrical. Vitamin C acts as a neuromodulator of 
glutamatergic, dopaminergic, cholinergic and GABAer-
gic transmission and the corresponding behaviours (5). 
Ascorbate mediates acetylcholine and catecholamine re-
lease from synaptic vesicles. Intracellular ascorbate is es-
sential for the protection from oxidant stress.
The role of vitamin C in cognition, mood and behav-
iour has been most extensively studied in memory and lo-
comotor activity in animal models. Age-related and toxic 
memory deficits in mice have been reversed by intraperi-
toneal ascorbate (18). Another effect is anxiety reduction 
(5). There are also some inconclusive studies about vitamin 
C’s cognitive effects. Acute vitamin C and D deficiency is 
highly prevalent among patients in acute care (19), and 
these patients often have mood disturbance and cognitive 
dysfunction due to these hypovitaminoses. In a random-
METABOLISM
Vitamin C is synthesized from glucose by many animals, 
with the exception of humans and some other species that 
are unable to synthesize this vitamin due to enzyme muta-
tions that make them dependent on food resources (4). With 
oral vitamin C intake, the plasma and tissue concentrations 
are strictly controlled by absorption, tissue accumulation, 
renal reabsorption and the rate of utilization, which main-
tains plasma concentrations up to 100 mmol/l. With supple-
mentation, the plasma concentrations do not exceed 250 
mmol/l and are frequently less than 150 mmol/l (6). 
Normally, the whole-body vitamin C content is ap-
proximately 20 mg/kg, or 1500 mg (7). In restricted intake, 
ascorbic acid is lost at a rate of 3% of the whole-body con-
tent per day. Plasma ascorbate levels between 20 and 80 
mmol/l are considered normal. Leukocyte ascorbate is a 
better indicator of vitamin C status than the plasma levels.
The oxidized form of ascorbate is dehydroascorbic acid 
(DHA), which is transported to and from the cells via facili-
tated diffusion through the ubiquitous GLUT family (GLUTs) 
glucose transporters (5). In cells, DHA is reduced to ascor-
bate. The ascorbate transporters sodium-dependent vitamin 
C transporter 1 and 2 (SVCT1 and SVCT2) are fundamen-
tal for controlling the pools and cellular contents of vitamin 
C (8). SVCT1 enables vitamin C absorption in the intestine. 
Ascorbate cannot cross the blood-brain barrier unless it is 
converted to DHA. SVCT2 is primarily located in the brain 
and neuroendocrine tissues, enabling intracellular neuronal 
concentrations to be increased 20- to 60-fold compared to 
the plasma concentration. It is a potential protective factor in 
brain capillary endothelial cells under ischaemia (9). SVCT2 
is also present in the peripheral nervous tissue, where it pro-
motes myelination through the formation of the extracellular 
matrix (10). Trials with vitamin C in Charcot-Marie-Tooth 
type 1A patients did not show any benefit (11, 10). Ascorbic 
acid is important for the hydroxylation of lysine and proline 
residues in the collagen in connective tissues (12).
Vitamin C is an important regulator of intracellular re-
dox status by maintaining sulphydryl compounds, particu-
larly glutathione, in their reduced state (13). It can repair 
protein hydroperoxides by regenerating the parent amino 
acids through reduction. Free radicals convert ascorbic 
acid to DHA, which is reconverted via the glutathione 
enzyme complex. Vitamin C can regenerate other antioxi-
dants, such as vitamin E, and protects folic acid. Vitamin C 
reduces copper and iron.
VITAMIN C DEFICIENCY 
Scurvy is the manifestation of vitamin C deficiency and 
is a potentially fatal disease. It has been recognized for many 
centuries. Patients demonstrate pain in the extremities 
from a failure of osteoid formation, easily occurring gingi-
val bleeding and other haemorrhagic manifestations, as well 
as hair and tooth loss, swelling, ulcerations, and ultimately 
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odological limitations (25). Avoiding vitamin C deficiency with 
adequate food intake is more beneficial than taking supple-
ments, but more well-designed studies are needed (28). The 
likely scenario in AD is that there is a shortage of vitamin C. 
Therefore, the brain uses ascorbate from the peripheral pools 
to ensure the adequate antioxidant capacity of the brain and re-
duce the oxidative stress involved in AD pathophysiology (25). 
Very high doses of vitamin C have been shown to be 
toxic to tumour cells in clinical and experimental studies 
(29). Pharmacologic ascorbate has cytotoxic properties 
against cancer cells in experimental murine brain tumour 
(glioblastoma) models (6). 
Oxidative injury is considered to be an important 
pathogenic mechanism in Parkinson’s disease, with se-
vere decreases in dopaminergic transmission. Ascorbate 
improves the bioavailability of levodopa and partially pro-
tects dopaminergic neurons from MPTP toxicity (5).
Ischaemic small vessel disease of the brain with white 
matter lesions correlates with cognitive status in both older 
and younger populations (30). Common vascular risk fac-
tors are present, but some risk factors still unknown. Vita-
min C may have favourable actions in ischemic brain dis-
ease as well. A meta-analysis of prospective studies revealed 
a significant inverse association between dietary vitamin C 
intake, blood levels of vitamin C and stroke risk (31). Data 
about ascorbic acid supplements are sparse. The likely 
mechanisms are its strong antioxidant action, anti-inflam-
matory action, inhibition of smooth muscle proliferation, 
membrane protection but also its blood pressure-lowering 
effects that slow the progression of atherosclerosis (31). 
In patients with severe head injury, administration of 
high doses (up to 10 grams) of vitamin C led to a significant 
stabilization of the perilesional edema and a reduction of 
hospital mortality (32).
In adults, neurogenesis only occurs in limited, but crucial 
brain areas (the hippocampus, olfactory bulb, periventricu-
lar area and subependymal hypothalamus) (1). It is of utmost 
importance that vitamin C is present in adequate quantities 
for stem cell generation, proliferation and differentiation (33). 
It is also crucial for neural stem cell generation, proliferation 
and differentiation during embryonic development. 
INDICATIONS AND DOSING
The recommended dietary allowance (RDA) is primarily 
based on the prevention of deficiency disease and not on 
prevention of chronic disease. The RDAs are listed below. 
Infants 
0-6 months 40 mg/day 
7-12 months 50 mg/day 
Children 
1-3 years 15 mg/day 
4-8 years 25 mg/day 
9-13 years 45 mg/day 
Adolescents 14-18 years 
Males 75 mg/day Females 65 mg/day 
ized, double-blind study of short-term 1000 mg vitamin C 
supplementation was associated with a 71% reduction in 
mood disturbance and a 51% reduction in psychological 
distress with the normalization of vitamin C plasma lev-
els. However, daily 5000 IU vitamin D intake increased the 
plasma levels, but not to the normal level, and did not im-
prove mood or decrease distress (19).
As oxidative stress is involved in the pathophysiology of 
neurodegenerative diseases, ascorbic acid has therapeutic 
potential in ischaemic stroke, Alzheimer’s disease (AD), Par-
kinson’s disease and Huntington’s disease. It protects neurons 
from glutamatergic excitotoxicity. In many studies, ascorbic 
acid protected cerebral tissue, which was attributed to its an-
tioxidant capacity (20). In an experimental model, vitamin C 
dose-dependently inhibited interleukin-1β (IL-1β)-mediated 
PGE2 synthesis in a human neuronal cell line, which was in-
creased synergistically in combination with aspirin (20). 
The main etiopathogenetic factor in Alzheimer’s dis-
ease is amyloid beta, which is derived from the amyloid 
precursor protein (APP) and exists in an oligomeric sol-
uble form as well as in deposits called senile plaques (21). 
The physiological role of APP is different after cleavage of 
the N-terminal ectodomain, which acts as a growth factor, 
while the C-terminal endodomain has a role in cell adhe-
sion and gene regulation (22). It is not clear whether am-
yloid beta has any physiological roles. Vitamin C plasma 
and CSF levels are reduced in AD despite regular nutrition 
and supplement intake reduces the AD incidence (5). 
Data from the Cache County Study showed that use of vi-
tamin E and vitamin C supplements in combination reduces 
the prevalence and incidence of Alzheimer’s disease (23). 
Additional analysis from the same study showed that higher 
vitamin C intake alone was associated with higher cognitive 
function at baseline on a Modified Mini-Mental State exami-
nation (3MS) and the patients had lesser cognitive decline 
compared with those with lower vitamin C intake (24).
Oxidative stress causes lipid peroxidation in neuronal 
membranes; the reactive products have cytotoxic and geno-
toxic properties that alter proteins and DNA and interact with 
other risk factors to promote neurodegeneration leading to AD 
(25). Ascorbate is involved in oligosaccharide metabolism and 
could preclude the formation of toxic amyloid beta oligomers, 
which are potentially produced in excess with lower plasma lev-
els of vitamin C (22). In a study of patients with moderate AD, 
the CSF: plasma ascorbic acid ratio predicted cognitive decline, 
possibly as an index of vitamin C availability to the brain (17). 
The use of combined antioxidants (vitamins C and E as well 
as non-steroidal anti-inflammatory drugs) in elderly patients in 
the Cache County Study had a protective effect on cognitive 
decline and the development of Alzheimer’s disease, but only 
in participants with the APOE epsilon 4 allele (26).
In a murine model of AD, the addition of vitamin C can 
improve spatial learning (27). A meta-analysis of the large 
population-based studies using a self-reported questionnaire 
produced inconclusive results, with the majority unable to de-
cisively confirm the association of ascorbate intake or supple-
mentation and AD. However, there were considerable meth-
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CONCLUSION
Vitamin C is crucial for normal development and bodi-
ly functions in human adulthood; however, humans are 
not capable of producing vitamin C. It has many important 
functions. Ascorbic acid is one of the main antioxidative 
agents in the human body, particularly the brain. Its defi-
ciency is classically expressed as scurvy, but subclinical de-
ficiencies are probably much more frequent. This opens a 
potential field of interest for vitamin C therapy in neurode-
generative, cerebrovascular and affective diseases, as well 
as cancer, brain trauma and others. Various dosing regimes 
are used; however, ascorbate is safe, even in high doses for 
protracted periods. Better designed studies are needed to 
elucidate all of the potential therapeutic roles of vitamin C. 
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